ENA Respiratory has welcomed $2.98 million in funding from Biointelect Venturer to support its first Australian study of INNA-051 in adults with asthma, expanding the clinical program for a once-weekly nasal spray intended to strengthen the body’s early defences against common respiratory viruses.

Vitrafy Life Sciences has secured its first foothold in the United States cell and gene therapy market through an agreement with Charter Medical to install its cryopreservation technology in the North Carolina company’s Innovation Hub.

Six Australian companies developing vaccines, antiviral treatments, and vaccine-production technologies will share $10.48 million in Biointelect Venture's first funding round.

Melbourne company Cartherics is joining forces with the Zucker Institute at the Medical University of South Carolina to investigate whether a novel antibody can strengthen next-generation immune cell therapies for solid tumours and endometriosis.

Percheron Therapeutics has secured firm commitments for a $2.3 million institutional placement, providing what the company says is full funding for a new clinical trial of its lead drug candidate, HMBD-002, in acute myeloid leukaemia and myelodysplastic syndrome.

Alterity Therapeutics has secured an underwriting agreement that could provide at least $4.2 million in additional funding as it prepares to begin its planned Phase 3 clinical trial of ATH434 for multiple system atrophy.

Tetratherix has exported its first commercial shipment of Tetramatrix polymer to the United States, marking the start of product revenue for the ASX-listed company’s Precision Medicine franchise.

Avecho Biotechnology has restarted recruitment for the final stage of its pivotal Phase 3 trial of a cannabidiol capsule designed to treat insomnia, after an independent review found the study could continue without increasing its planned sample size.

Genetic Signatures and Microba Life Sciences have announced they are in preliminary discussions about a potential merger that would combine rapid infectious disease testing with gut microbiome profiling and create a larger ASX-listed diagnostics business.

Mesoblast reported a sharp rise in revenue as sales of its cell therapy, Ryoncil, accelerated in the United States, while its chronic low back pain program moved closer to a decisive clinical readout.

Neuren Pharmaceuticals has announced it will begin paying dividends to shareholders for the first time, following a sharp increase in royalty income from its Rett syndrome treatment, DAYBUE (trofinetide).

Chief executive Cheryl Maley said the year brought advances in the company’s lead radiopharmaceutical program, new strategic partnerships, and further validation of DEP technology's potential in targeted cancer treatment.

Noxopharm says new laboratory findings strengthen the case for using its Sofra technology to help the immune system recognise cancer cells after treatments such as chemotherapy or radiotherapy kill them.

Entropy Neurodynamics has signed an agreement with the University of California, San Francisco (UCSF), to develop a US Phase 2 trial comparing its intravenous psilocin treatment TRP-8803 with the widely used antidepressant escitalopram in young adults with major depressive disorder.

Chairman Roby Zomer said the development marked the program’s transition from a commercial agreement into formal engagement with the FDA’s veterinary medicines division.

Neuren Pharmaceuticals has reached a major milestone in the global commercialisation of trofinetide after the European Commission granted marketing authorisation for DAYBU to treat neurobehavioural symptoms associated with Rett syndrome.

Genetic Signatures has emerged from a year of restructuring with smaller losses, lower cash burn, and a clearer plan to rebuild growth, despite a decline in revenue amid challenging conditions in its core Australian market.